1. Scrip
  2. >>New Products

ViiV/Janssen Forge Two-Drug Future For HIV With SWORD Filings

 
• By Alexandra Shimmings

The battle of the HIV giants ViiV Healthcare and Gilead Sciences continues with the first filing for a two-drug regimen for use against HIV infection in the US and EU.

boat anchored in a bay, luxury yacht
Why rock the boat? Will doctors go for a two-drug regimen? • Source: Shutterstock

ViiV Healthcarehas filed for US and EU approval of a two-drug regimen for HIV consisting of its integrase inhibitor dolutegravir and Janssen Inc.'s non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant) in a single tablet. If approved, this will be first two-drug regimen for the maintenance treatment of HIV-1 infection, and will offer patients an NRTI-free option.

In the US, ViiV is using a priority review voucher to speed the review and hopefully get the product approved...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: ASCO Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

More from Scrip

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

 
• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

Sanofi Cements RSV Dominance As Merck & Co. Rival Awaits FDA D-Day

 
• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

Pipeline Watch: ASCO Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.